Hospital Clinico Universitario Lozano Blesa

Neoplasms (C04)

The oncology department at Hospital Clinico Universitario Lozano Blesa focuses on advancing treatment for a wide range of cancers, including breast cancer, non‑small cell lung cancer, and ovarian malignancies. Trials aim to test new targeted therapies, immunotherapy combinations, and novel maintenance strategies to improve survival and reduce recurrence.

Advanced triple‑negative breast cancer
HER2‑positive metastatic breast cancer
Advanced or metastatic non‑small cell lung cancer
High‑grade serous ovarian cancer
Renal cell carcinoma
Urothelial carcinoma

These studies seek to expand therapeutic options and personalize care for patients with aggressive or treatment‑resistant tumors.

Cardiovascular Diseases (C14)

Research at the site includes investigations into heart failure and coronary conditions, with an emphasis on evaluating novel pharmacologic agents such as angiotensin receptor‑neprilysin inhibitors for transthyretin amyloid cardiomyopathy.

Acute heart failure
Heart failure with preserved ejection fraction
Spontaneous coronary artery dissection
Cardiovascular complications of metabolic disease

The goal is to improve cardiac function, reduce hospitalizations, and extend quality‑adjusted life years for patients with serious heart conditions.

Respiratory Tract Diseases (C08)

The department conducts trials targeting lung disorders, from chronic obstructive pulmonary disease to various forms of lung cancer. Studies assess the safety and efficacy of inhaled bronchodilators, as well as immunotherapy‑based regimens for malignant disease.

Chronic obstructive pulmonary disease (COPD)
Small‑cell lung cancer
Non‑small cell lung cancer with KRAS G12C mutation
Advanced squamous cell carcinoma of the lung

By integrating respiratory function outcomes with oncologic endpoints, these trials aim to enhance both symptom control and survival.

Immune System Diseases (C20)

Investigations address autoimmune and inflammatory conditions, exploring biologic agents and small‑molecule inhibitors to modulate immune pathways. Trials include patients with inflammatory bowel disease and rare vasculitides.

Moderately to severely active Crohn’s disease
Moderately to severely active ulcerative colitis
Eosinophilic granulomatosis with polyangiitis (EGPA)
Chronic lymphocytic leukemia (immune‑related aspects)

The research seeks to achieve durable remission while minimizing systemic side effects.

Digestive System Diseases (C06)

Clinical work focuses on gastrointestinal malignancies and functional disorders, evaluating new chemotherapeutic combinations and targeted agents for colorectal cancer and gastric adenocarcinoma, as well as supportive therapies for malabsorption.

Metastatic colorectal cancer
Gastric adenocarcinoma
Intestinal malabsorption in preterm infants
Inflammatory bowel disease (Crohn’s, ulcerative colitis)

Outcomes aim to increase response rates, enable surgical resection, and improve nutritional status.

Eye Diseases (C11)

The ophthalmology research program evaluates innovative intravitreal therapies for retinal conditions, including treatments for diabetic macular edema and geographic atrophy associated with age‑related macular degeneration.

Diabetic macular edema
Geographic atrophy secondary to AMD
Neovascular age‑related macular degeneration (wet AMD)

These studies aim to preserve visual acuity and reduce disease progression in patients at risk of vision loss.

Female Urogenital Diseases and Pregnancy Complications (C13)

Trials in this area address gynecologic oncology and reproductive health, testing novel agents for advanced ovarian, endometrial, and cervical cancers, as well as assessing adjuvant therapies to prevent recurrence.